Morgan Stanley Cuts BridgeBio Pharma (BBIO) Price Target to $87
Key Points
- On October 21, 2026, Morgan Stanley kept its Overweight rating on BridgeBio Pharma, Inc. (NasdaqGS: BBIO) while lowering its price target from $97.00 to $87.00.
- Morgan Stanley's $87 price target implies 26.96% upside from BridgeBio Pharma, Inc.'s ($BBIO) current $68.53 share price.
- The biopharmaceutical company recently posted trailing-twelve-month revenue of $713.1 million with a net margin of -97.0%, and its next earnings release is scheduled for October 29, 2026.
- Other Wall Street research firms covering the stock carry a consensus strong buy recommendation with an average price target of $107.82 across 22 analyst opinions.
Since the rating, $BBIO is up 0.8% to date (from the $67.74 close on Oct 21, 2026).
Get BridgeBio Pharma text alerts
We text you when insiders, Congress, analysts or big funds move on $BBIO.
By entering your mobile number and tapping the sign-up button, you provide express written consent to receive recurring automated text messages from TradeTexts at that number, including stock alerts about SEC filings, insider and congress trades, analyst ratings, hedge fund moves, and earnings results. Consent is not a condition of any purchase. Message frequency varies. Messages are not investment advice. Message and data rates may apply. Reply HELP for help and STOP to opt out at any time. See our Terms and Privacy Policy.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated BridgeBio Pharma, Inc. alert may contain errors. Disclosures
On October 21, 2026, Morgan Stanley maintained its Overweight rating on BridgeBio Pharma, Inc. (NasdaqGS: BBIO) while lowering its price target from $97.00 to $87.00. The update arrived via a research note issued by the firm on the same day the stock closed at $67.74.
BBIO
BridgeBio Pharma, Inc.
Morgan Stanley's Call on BridgeBio Pharma
In its October 21, 2026 research note, Morgan Stanley kept an Overweight rating on BridgeBio Pharma while reducing its price target to $87.00 from $97.00. The firm joins a broader group of major financial institutions evaluating the biotechnology developer's pipeline and market position.
Other Institutional Activity in BridgeBio Pharma
Major institutional investors made notable adjustments to their holdings in BridgeBio Pharma during the second quarter. Jupiter Topco LLC grew its holdings by 7,055,139 shares, ending with 14,110,278 shares worth about $964.0 million. Kohlberg Kravis Roberts & Co. L.P. kept its stake steady at 13,260,971 shares valued at roughly $906.0 million. Farallon Capital Management LLC grew its holdings by 1,377,652 shares, ending with 10,743,063 shares worth about $734.0 million. Viking Global Investors, L.P. reduced its position by 1,893,679 shares, ending with 9,949,219 shares valued at roughly $679.7 million. Two Sigma Investments, LP grew its holdings by 1,601,523 shares, ending with 4,722,185 shares worth about $322.6 million.
BridgeBio Pharma, Inc. Stock Up 1.2%
Shares of BridgeBio Pharma recently traded around $68.53 as of October 22, 2026, putting the stock up about 1.2% since its $67.74 close on October 21. The stock is positioned below its 50-day moving average of $71.95 and below its 200-day moving average of $72.96. Over the past 52 weeks, shares have traded as low as $52.75 and as high as $93.42. The company carries a market capitalization of roughly $13.4 billion and a beta of 0.97.
$BBIO price target
BridgeBio Pharma, Inc. daily closes and this analyst's $87 target. Not advice.
Recent Earnings
BridgeBio Pharma reported trailing-twelve-month revenue of $713.1 million alongside a net profit margin of -97.0%. The company posted basic earnings per share of -$3.56 over the same trailing period. The next quarterly earnings report is scheduled for release on October 29, 2026.
Insider Buying and Selling at BridgeBio Pharma, Inc.
Company insiders executed several transactions leading up to the recent analyst update. Director Jennifer E. Cook disposed of 148,589 shares on July 9, 2026, with a total value of $13.2 million. Officer Maricel Apuli sold 2,000 shares on July 30, 2026, at an average price of $80.06 for a total value of $160,120. Chief Executive Officer Neil Kumar parted with 44,980 shares on August 19, 2026, valued at $3.7 million, followed by an additional sale of 10,000 shares on September 17, 2026, worth $690,847.
Analysts Set New Price Targets
Wall Street coverage on BridgeBio Pharma includes multiple updates ahead of the latest research note. On September 10, 2026, HC Wainwright & Co. reiterated a Buy rating with a $120.00 price target. Barclays maintained its Overweight rating on October 7, 2026, moving its target from $157.00 to $156.00. Citigroup kept a Neutral rating on October 19, 2026, while lowering its target from $94.00 to $91.00. Piper Sandler maintained an Overweight rating on October 19, 2026, raising its target from $115.00 to $120.00. Across the wider analyst community, the stock holds a consensus strong buy recommendation and an average price target of $107.82 from 22 tracked opinions.
About BridgeBio Pharma
BridgeBio Pharma, Inc. is a Palo Alto-based biopharmaceutical company focused on discovering, developing, and delivering targeted medicines for patients suffering from genetic diseases. The firm advances a diverse pipeline of therapeutic candidates aimed at addressing the root causes of severe genetic conditions. Research updates and valuation adjustments from major institutions like Morgan Stanley help frame how the market assesses the company's clinical progress and commercial potential.
Bottom Line
Investors are closely monitoring upcoming milestones as BridgeBio Pharma prepares to release its next financial results on October 29, 2026. The shift in price targets among major banking firms reflects evolving expectations for the biotechnology developer's pipeline.
Related Filing Alerts
Source: Morgan Stanley's rating change on $BBIO (Oct 21, 2026). Written by software, not financial advice. How we make alerts